The Impact of Vaccination Time on the Antibody Response to an Inactivated Vaccine against SARS‐CoV‐2 (IMPROVE‐2): A Randomized Controlled Trial

Abstract

There is still controversy about whether severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination at different times of day will induce a stronger immune response. Therefore, a randomized controlled trial (ChiCTR2100045109) is conducted to investigate the impact of vaccination time on the antibody response to the inactivated vaccine against SARS‐CoV‐2 from April 15 to 28, 2021. Participants are randomly assigned in a 1:1 ratio to receive inactivated SARS‐CoV‐2 vaccine in the morning or afternoon. The primary endpoint is the change of neutralizing antibody between baseline and 28 days after the second dose. In total, 503 participants are randomized, and 469 participants (238 in the morning group and 231 in the afternoon group) complete the follow‐up. There is no significant difference in the change of neutralizing antibody between baseline and 28 days after the second dose between the morning and afternoon groups (22.2 [13.2, 45.0] AU mL−1 vs 22.0 [14.4, 40.7] AU mL−1, P = 0.873). In prespecified age and sex subgroup analyses, there is also no significant difference in the morning and afternoon group (all P > 0.05). This study demonstrates that the vaccination time does not affect the antibody response of two doses of inactivated SARS‐CoV‐2 vaccine.